*For medical professionals only
2024 ASCO Sneak Peek!
Finishing | It's orange, it's not orange
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4. As one of the largest, most academically and most authoritative clinical oncology conferences in the world, the ASCO Annual Meeting brings together many world-class oncology experts every year to discuss the most cutting-edge clinical oncology research results and tumor treatment technologies.
A few days ago, the abstract title of the ASCO Annual Meeting has been announced, and the highlights of the blockbuster research continue! The editor hereby compiles some of the major research titles of plenary conferences, oral abstracts, quick oral abstracts, and clinical science seminars in the field of gastroesophageal cancer and colorectal cancer for your reference!
Figure 1 Screenshot of ASCO's official website
Exciting research continues in the field of gastroesophageal cancer
■ Description: LBA1
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy（FLOT protocol） to neoadjuvant chemoradiation（CROSS protocol） in patients with adenocarcinoma of the esophagus（ESOPEC trial）
Prospective, randomized, multicenter, phase III ESOPEC study: comparing perioperative chemotherapy (FLOT regimen) and neoadjuvant chemoradiotherapy (CROSS regimen) in patients with esophageal adenocarcinoma
汇报者:Jens Hoeppner,德国比勒费尔德大学
■ Abstract: LBA4001
Effect of chemotherapy/targeted therapy alone vs chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction：The IKF-575/RENAISSANCE phase III trial
Phase III IKF-575/RENAISSANCE Study: To compare the effects of chemotherapy/targeted therapy alone versus chemotherapy/targeted therapy followed by curative surgical resection on survival and quality of life in patients with localized metastatic adenocarcinoma of the stomach or gastroesophageal junction (GC/GEJ).
汇报者:Salah-Eddin Al-Batran,德国法兰克福大学癌症中心
■ Description: LBA4002
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients （pts） with advanced HER2-negative gastric or gastroesophageal junction （GEJ） cancer：the ARMANI phase III trial
Phase III ARMANI study: ramucirumab + paclitaxel versus oxaliplatin-based chemotherapy regimens for maintenance therapy in patients with HER2-negative advanced GC/GEJ cancer
Filippo Pietrantonio, Foundation of the National Institute of Oncology, Italy
■ Abstract number: 4000
A phase II/III study of peri-operative nivolumab（nivo） and ipilimumab（ipi） in patients（pts） with locoregional esophageal（E） and gastroesophageal junction（GEJ） adenocarcinoma：Results of the neoadjuvant pathologic complete response（pCR） rate（ECOG-ACRIN EA2174）
Phase II/III ECOG-ACRIN EA2174 Study: Neoadjuvant pathologic complete response (pCR) rate results in patients with locoregional esophageal (E) and epilimumab in patients with locoregional esophageal (E) and GEJ adenocarcinoma
Jennifer Eads, Abramson Cancer Center, University of Pennsylvania
■ Abstract: 4009
Efficacy of disitamab vedotin（RC48） plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma：A multicenter，single-arm，phase II trial（RCTS）
Efficacy of vedicitumab (RC48) + tislelizumab + S-1 in the first-line treatment of HER2-overexpressing advanced GC/GEJ adenocarcinoma: a multicenter, single-arm, phase II study (RCTS)
Presenter: Prof. Li Song, Qilu Hospital, Shandong University
■ Abstract: 4012
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction（G/GEJ） cancer who failed immunochemotherapy：A multicenter， double-blind， randomized trial
Efficacy and safety of cadonilimab + pulocimab and paclitaxel as second-line therapies in patients with advanced G/GEJ cancer who have failed immunochemotherapy: a multicenter, double-blind, randomized trial
Prof. Xiaotian Zhang, Peking University Cancer Hospital
■ Abstract: 4013
Use of artificial intelligence–based digital pathology to predict outcomes for immune checkpoint inhibitor therapy in advanced gastro-esophageal cancer
Predicting the efficacy of immune checkpoint inhibitor (ICI) therapy for advanced gastroesophageal cancer using AI-based digital pathology
Feyisope Eweje, Stanford University School of Medicine, USA
Colorectal cancer hotspot study to be announced soon,
It's worth the wait!
■ Abstract: LBA3501
Surgery versus thermal ablation for small-size colorectal liver metastases （COLLISION）：An international， multicenter， phase III randomized controlled trial
International multicenter phase III randomized controlled COLLISION study: comparing the outcomes of surgery and thermal ablation in the treatment of liver metastases in small colorectal cancer (CRC).
汇报者:Martijn Meijerink,荷兰阿姆斯特丹大学
■ Abstract: LBA3502
Primary outcome analysis of the ORCHESTRA trial：A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer
Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of multi-organ metastatic colorectal cancer (mCRC) in patients receiving first-line palliative systemic therapy plus tumor resection
汇报者:Love Gootjes,荷兰阿姆斯特丹大学
■ Abstract: LBA3504
NEOPRISM-CRC：Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer
NEOPRISM-CRC study: pembrolizumab neoadjuvant therapy for high-risk stage II or stage III dMMR/MSI-H CRC stratified according to tumor mutational burden
汇报者:Kai-Keen Shiu, Institute of Cancer Disease, University of Bodun, UK
■ Abstract: LBA3510
Overall survival （OS） of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab （soto+pani） versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer （mCRC）
III 期CodeBreaK 300 研究的总生存 期(OS)数据:Sotorasib联合panitumumab (soto+pani)The Story of the Dead CKRAS G12C 突变mCRC 患者
Marwan Fakih, City of Hope Comprehensive Cancer Center, USA
■ Description: LBA3511
Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors（TNTCRT）：A multicenter，randomized，open-label，phase 3 trial
A multicenter, randomized, open-label phase III TNTCRT study: a full course of neoadjuvant long-term radiotherapy versus concurrent chemoradiotherapy in patients with locally advanced CRC with high-risk factors
Presenter: Prof. Xin Wang, West China Hospital, Sichuan University
■ Abstract: LBA3512
Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer
Durable complete response to PD-1 inhibitor monotherapy in mismatch repair deficient (dMMR) locally advanced CRC
Andrea Cercek, Memorial Sloan Kettering Cancer Center, USA
■ Abstract: 108
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer：Overall survival and updated 5-year results from the randomized DYNAMIC trial
ctDNA analysis to guide adjuvant therapy for stage II colon cancer: OS rates and latest 5-year follow-up results from the DYNAMIC study
Presented by: Jeanne Tie, Peter McCollum Cancer Centre, Australia
■ Abstract: 3500
Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases：A prospective multicentric randomized trial （TRANSMET）
A prospective, multicenter, randomized TRANSMET study to explore chemotherapy and liver transplantation versus chemotherapy alone in patients with unresectable CRC liver metastases
汇报者：Rene Adam，巴黎萨克雷大学
Abstract: 3503
Nivolumab（NIVO） plus ipilimumab（IPI） vs chemotherapy（chemo） as first-line（1L） treatment for microsatellite instability-high/mismatch repair-deficient（MSI-H/dMMR） metastatic colorectal cancer（mCRC）：Expanded efficacy analysis from CheckMate 8HW
Nivolumab in combination with ipilimumab versus chemotherapy as first-line treatment for microsatellite instability (MSI-H)/dMMR metastatic mCRC: results from an extended efficacy analysis of the CheckMate 8HW study
Presented by: Heinz-Josef Lenz, Norris Comprehensive Cancer Center, University of Southern California, USA
Abstract: 3505
Neoadjuvant treatment of IBI310（anti-CTLA-4 antibody） plus sintilimab（anti-PD-1 antibody） in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer：Results from a randomized，open-labeled，phase Ib study
IBI310 (anti-CTLA-4 antibody) in combination with sintilimab (anti-PD-1 antibody) as neoadjuvant therapy in patients with MSI-H/dMMR CRC: Results of a randomized, open-label phase Ib study
Presenter: Prof. Ruihua Xu, Sun Yat-sen University Cancer Center
Abstract: 3506
FU/FA maintenance therapy with or without panitumumab（pmab） in RAS wild-type metastatic colorectal cancer（mCRC）（PanaMa， AIO KRK 0212）：Updated efficacy analyses
AIO KRK 0212研究:RAS野生型mCRC的FU/FA维持治疗联合或不联合Panitumumab(pmab)的最新疗效分析
汇报者:Dominik Modest,德国柏林夏里特医学院
■ Abstract: 3507
Acquired gene alteration patterns and post-progression survival：PARADIGM study analysis
Patterns of acquired genetic alterations and survival after progression: an analysis of the PARADIGM study
汇报者:Hiroyuki Uetake, Japan 东京Medical University
Abstract: 3508
ARC-9：A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer （mCRC）
ARC-9 Study: A randomized study evaluating the efficacy of an etrumadenant-based combination regimen in previously treated patients with mCRC
Zev Wainberg, David Geffen School of Medicine, University of California, Los Angeles, USA
■ Abstract: 3509
Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC （MOUNTAINEER）
Tucatinib和曲妥珠单抗治疗HER2阳性mCRC:II期MOUNTAINEER研究的最终结果
John Strickler, Duke University Medical Center, USA
■ Abstract: 3513
Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer。
Time-dependent effects of human papillomavirus (HPV) ctDNA assay as a prognostic biomarker for anal cancer
Van Morris, MD Anderson Cancer Center, USA
■ Abstract: 3515
First-in-human study of ABBV-400，a novel c-Met–targeting antibody-drug conjugate，in advanced solid tumors：Results in colorectal cancer
First-in-human trial of ABBV-400 (novel c-Met targeted antibody-drug conjugate) in advanced solid tumors: CRC study results
汇报者：Manish Sharma，START Midwest
■ Abstract: 3516
Three-year disease-free survival after transanal vs。 laparoscopic total mesorectal excision for rectal cancer（TaLaR）：A randomized clinical trial
TaLaR Study: To explore the three-year disease-free survival rate after transrectal or laparoscopic total mesorectal resection for rectal cancer
Presenter: Prof. Kang Liang, The Sixth Affiliated Hospital of Sun Yat-sen University
Abstract: 3517
Updated results from ERAS-007 plus encorafenib and cetuximab（EC） in patients （pts） with EC-naïve metastatic BRAF V600E colorectal cancer（CRC） in the phase 1b/2 HERKULES-3 study
Phase I, II. HERKULES-3 study: Updated results from ERAS-007 in combination with encorafenib and cetuximab (EC) in EC-naïve patients with BRAF V600E mutant mCRC
Presented by: Aparna Parikh, Massachusetts General Hospital, USA
Exciting information is waiting for you
Editor in charge: Sheep
*The medical community strives to publish professional and reliable content, but does not make any commitment to the accuracy of the content; The parties involved are invited to separately check when adopting or using this as a basis for decision-making.
